Clinical Trial Update: Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study comparing Zevalin alone versus Zevalin with motexafin gadolinium in rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma; st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Motexafin Gadolinium (motexafin gadolinium)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2021-10-04